Compare HBT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBT | CRVS |
|---|---|---|
| Founded | 1920 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2019 | 2016 |
| Metric | HBT | CRVS |
|---|---|---|
| Price | $35.68 | $14.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $30.75 | $30.17 |
| AVG Volume (30 Days) | 129.7K | ★ 757.8K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | 7.96 | ★ 48.04 |
| EPS | ★ 1.12 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.73 | N/A |
| Revenue Next Year | $7.01 | N/A |
| P/E Ratio | $32.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.36 | $5.29 |
| 52 Week High | $37.51 | $26.95 |
| Indicator | HBT | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 58.06 | 51.49 |
| Support Level | $35.34 | $14.24 |
| Resistance Level | $37.17 | $16.66 |
| Average True Range (ATR) | 0.73 | 0.70 |
| MACD | -0.25 | -0.03 |
| Stochastic Oscillator | 41.90 | 56.16 |
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking. It generates revenue from Card income, Wealth management fees, and Service charges on deposit accounts.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.